GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Cyclically Adjusted PB Ratio

Albireo Pharma (FRA:BDQM) Cyclically Adjusted PB Ratio : (As of Jun. 09, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Albireo Pharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Albireo Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Cyclically Adjusted PB Ratio Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Albireo Pharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Albireo Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albireo Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's Cyclically Adjusted PB Ratio falls into.



Albireo Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Albireo Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, Albireo Pharma's adjusted Book Value per Share data for the three months ended in Sep. 2022 was:

Adj_Book=Book Value per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=4.884/125.2265*125.2265
=4.884

Current CPI (Sep. 2022) = 125.2265.

Albireo Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201212 44.984 96.871 58.151
201303 37.545 98.209 47.874
201306 38.619 98.518 49.089
201309 34.679 98.790 43.959
201312 31.622 98.326 40.273
201403 25.155 99.695 31.597
201406 22.343 100.560 27.824
201409 22.993 100.428 28.671
201412 19.588 99.070 24.760
201503 18.408 99.621 23.139
201506 18.233 100.684 22.677
201509 17.013 100.392 21.222
201512 15.650 99.792 19.639
201603 13.017 100.470 16.224
201606 11.638 101.688 14.332
201609 11.017 101.861 13.544
201612 5.567 101.863 6.844
201703 4.637 102.862 5.645
201706 7.560 103.349 9.160
201709 6.529 104.136 7.851
201712 6.193 104.011 7.456
201803 10.918 105.290 12.985
201806 10.698 106.317 12.601
201809 9.785 106.507 11.505
201812 9.036 105.998 10.675
201903 8.189 107.251 9.562
201906 8.211 108.070 9.515
201909 7.278 108.329 8.413
201912 6.576 108.420 7.595
202003 6.854 108.902 7.881
202006 5.280 108.767 6.079
202009 9.426 109.815 10.749
202012 7.797 109.897 8.885
202103 6.474 111.754 7.254
202106 4.896 114.631 5.349
202109 8.013 115.734 8.670
202112 8.054 117.630 8.574
202203 6.893 121.301 7.116
202206 5.486 125.017 5.495
202209 4.884 125.227 4.884

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Albireo Pharma  (FRA:BDQM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Albireo Pharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Albireo Pharma (FRA:BDQM) Business Description

Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines